Home/Filings/4/0001126234-24-000115
4//SEC Filing

LALANDE KEVIN M. 4

Accession 0001126234-24-000115

CIK 0001126234other

Filed

Dec 12, 7:00 PM ET

Accepted

Dec 13, 9:31 PM ET

Size

17.7 KB

Accession

0001126234-24-000115

Insider Transaction Report

Form 4
Period: 2024-12-12
Transactions
  • Disposition to Issuer

    Common Stock

    2024-12-121,0760 total
  • Disposition to Issuer

    Common Stock

    2024-12-12730,4460 total(indirect: By Sante Health Ventures II, LP)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-12-123,3450 total
    Exercise: $3.42Exp: 2033-05-09Common Stock (3,345 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-12-123,3280 total
    Exercise: $2.35Exp: 2034-06-04Common Stock (3,328 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-12-122,9100 total
    Exercise: $10.36Exp: 2031-05-19Common Stock (2,910 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-12-125,6840 total
    Exercise: $7.78Exp: 2030-04-02Common Stock (5,684 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-12-123,4310 total
    Exercise: $8.18Exp: 2032-05-04Common Stock (3,431 underlying)
Footnotes (4)
  • [F1]Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
  • [F2]The reporting person is a managing director of SHV Management Services, LLC ("SHV Management"). SHV Management is the general partner of SHV Management Services, LP, which is the general partner of the partnership that directly owns the reported securities. The reporting person disclaims beneficial ownership of the securities reported except to the extent of his pecuniary interest, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all the reported securities for purposes of Section 16 or for any other purpose.
  • [F3]This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
  • [F4]Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.

Issuer

LUMOS PHARMA, INC.

CIK 0001126234

Entity typeother

Related Parties

1
  • filerCIK 0001587800

Filing Metadata

Form type
4
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 9:31 PM ET
Size
17.7 KB